Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia

Murtadha Al-Khabori, Mark D. Minden, Karen W L Yee, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Wei Xu, Joseph M. Brandwein

Research output: Contribution to journalArticle

14 Citations (Scopus)


All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber Cancer Institute), was used as the standard regimen for all patients (n=32). The two groups (DFCI and non-DFCI) had comparable baseline characteristics. Complete response rates were not significantly different between the DFCI- and non-DFCI-treated groups. The 3-year relapse free survival (RFS) and overall survival (OS) were significantly higher in the DFCI-treated group (p

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalLeukemia and Lymphoma
Issue number1
Publication statusPublished - Jan 2010



  • Acute lymphoblastic leukemia
  • Chemotherapeutic approaches
  • Prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this